Samsung Medical Center

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Subsidiary

Established: 1994-01-01

Employees: 501

Market Cap: -

Website: http://www.samsunghospital.com

Clinical Trials

Prospective Cohort for Adult Hemophagocytosis

Recruiting

Conditions: Hemophagocytic Lymphohistiocytoses

Interventions: Drug: Steroids
Drug: Etoposide

First Posted Date: 2017-04-17

Last Posted Date: 2024-08-07

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 81

Registration Number: NCT03117010

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III

Recruiting

Conditions: Lymphoma, Non-Hodgkin
Lymphoma, Hodgkin

Interventions: Drug: Chemotherapy

First Posted Date: 2017-04-17

Last Posted Date: 2024-12-02

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 600

Registration Number: NCT03117036

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Information and Communication Technology Based Centralized Clinical Trial Monitoring System for Insulin Dose Adjustment

Not Applicable

Completed

Conditions: Insulin-dependent Diabetes Mellitus
Diabetes Mellitus
Insulin Hypoglycemia

Interventions: Device: Algorithm-based feedback messages
Device: Personal Health Record

First Posted Date: 2017-04-13

Last Posted Date: 2019-04-05

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 112

Registration Number: NCT03112343

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

Phase 2

Withdrawn

Conditions: Biliary Tract Cancer

Interventions: Drug: Fluorouracil
Drug: Irinotecan Hydrochloride
Drug: leucovorin calcium

First Posted Date: 2017-04-12

Last Posted Date: 2022-06-15

Lead Sponsor: Samsung Medical Center

Registration Number: NCT03110510

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

Phase 2

Conditions: Biliary Tract Cancer

Interventions: Drug: Pemetrexed 500 MG
Drug: Erlotinib

First Posted Date: 2017-04-12

Last Posted Date: 2022-06-15

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 44

Registration Number: NCT03110484

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes

Phase 2

Completed

Conditions: Biliary Tract Cancer

Interventions: Drug: MK3475

First Posted Date: 2017-04-12

Last Posted Date: 2022-06-15

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 33

Registration Number: NCT03110328

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification

Phase 2

Terminated

Conditions: Small Cell Lung Cancer

Interventions: Drug: vistusertib (AZD2014)

First Posted Date: 2017-04-10

Last Posted Date: 2018-09-20

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 4

Registration Number: NCT03106155

Locations: 🇰🇷
Samsung Medical center, Seoul, Korea, Republic of

Concurrent Chemo-proton Radiotherapy With or Without Resection and Spacer Insertion for Loco-regional Recurrence of Previous Irradiated Rectal Cancer

Not Applicable

Conditions: Previously Irradiated Recurrent Rectal Cancer

Interventions: Radiation: Concurrent chemo-proton therapy

First Posted Date: 2017-03-31

Last Posted Date: 2018-06-28

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 24

Registration Number: NCT03098108

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

A Phase I Study of High Dose Simvastatin in Patients With Gastrointestinal Tract Cancer Who Failed to Standard Chemotherapy

Phase 1

Conditions: Stomach Cancer

Interventions: Drug: Simvastatin

First Posted Date: 2017-03-22

Last Posted Date: 2019-12-30

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 9

Registration Number: NCT03086291

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy

Phase 2

Completed

Conditions: Colo-rectal Cancer

Interventions: Drug: Pemetrexed
Drug: Tarceva 100Mg Tablet

First Posted Date: 2017-03-22

Last Posted Date: 2022-06-15

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 29

Registration Number: NCT03086538

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy